Latest news with #GileadSciencesInc
GMA Network
15-07-2025
- Health
- GMA Network
WHO recommends Gilead's twice-yearly injection for HIV prevention
The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the US health regulator approved the drug, giving patients new hope of interrupting virus transmission. The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care "While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus, WHO director-general. The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist. These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents. WHO has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly procedures. Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year. —Reuters
NZ Herald
18-06-2025
- Health
- NZ Herald
Gilead's twice-a-year HIV prevention shot wins regulatory approval in US
Gilead Sciences Inc said it won United States approval from Food and Drug Administration regulators for a drug to prevent HIV that only has to be given twice a year. That makes it a convenient new way to ward off infection in a wide range of people. In two
Yahoo
16-06-2025
- Business
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-05-2025
- Business
- Yahoo
Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK's antiviral programs, specifically the 'HB-400' & 'HB-500'. The company first invested $21.25 million in HOOK in 2023, with the aim of advancing its HIV program, i.e., through only the HB-500 program at that time. Gilead Sciences Inc. (NASDAQ:GILD) has also backed a merger between HOOK and Poolberg Pharma, in an attempt to make a stronger clinical-stage biopharmaceutical company focused on next-generation immunotherapies for cancer and other serious diseases HOOKIPA Pharma is a clinical-stage biopharmaceutical company that develops immunotherapies targeting infectious diseases based on its proprietary arenavirus platform. HOOK has a current market capitalization of over $19 million. Regarding the terms and timelines of the financing, the agreement will take place in three milestones. The first $3m will be paid out at the close of the deal. After that, a three-phase transfer plan will make HOOK eligible to receive $7m. The first phase will give HOOK access to the first tranche of $3m, and the remaining two phases will see HOOK receive $2 million for each phase. The deal is currently awaiting approval from the shareholders of HOOK. The company's share price peaked at $1.75 on May 21, 2025, and closed at $1.52 at the end of trading. While we acknowledge the potential of GILD, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Stock Market News for May 20, 2025
U.S. stock markets closed higher on Monday after a choppy session. Market participants remained concerned regarding downgrade of the U.S. sovereign credit rating. On the other hand, positive developments on the trade and tariff related front bolstered investors' sentiment. All three major stock indexes ended in positive territory. The Dow Jones Industrial Average (DJI) rose 0.3% or 137.33 points to close at 42,792.07. At intraday low, the blue-chip index was down by 307 points. Notably, 16 components of the 30-stock index ended in positive territory and 14 finished in negative zone. The tech-heavy Nasdaq Composite finished at 19,215.46, rising 0.02% due to strong performance of bigwigs. The major gainer of the tech-laden index was however Gilead Sciences Inc. GILD. The stock price of the biotech firm was up 3.6%. Gilead Sciences currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The S&P 500 was up by 5.22 points to finish at 5,963.60. The benchmark posted a six-day winning run. Eight out of 10 broad sectors of the broad-market index ended in positive territory and three in negative zone. The Health Care Select Sector SPDR (XLV) rose 1%. On the other hand, the Energy Select Sector SPDR (XLE) fell 1.3%. The fear-gauge CBOE Volatility Index (VIX) was up 5.2% to 18.14. A total of 19.41 billion shares were traded on Monday, higher than the last 20-session average of 17.34 billion. Decliners outnumbered advancers on the NYSE by a 1.01-to-1 ratio. On Nasdaq, a 1.3-to-1 ratio favored declining issues. On May 16, after the closing bell, Moody's Investor Services downgraded the U.S. sovereign credit rating by one notch to Aa1 from Aaa citing the growing burden of financing the federal government's outstanding budget deficit of a mammoth $36 trillion and the rising cost of rolling over existing debt under the high-interest rate regime. According to the rating agency, "Successive US administrations and Congress have failed to agree on measures to reverse the trend of large annual fiscal deficits and growing interest costs.' The rating agency changed its outlook on the United States to "stable" from "negative." Following the development, the yield on the long-term U.S. 30-Year Treasury Note spiked more than 5% and the yield on the benchmark 10-Year U.S. Treasury Note climbed to 4.5%. The 10-year yield is closely link to the mortgage rate. After two days of high-level negotiations, the United States and China have decided to for a 90-day pause of tariff implementations. On May 12, the United States and China agreed in a discussion in Switzerland to reach a temporary agreement that 'reciprocal' tariffs between both countries will be cut from 125% to 10%. Meanwhile, United States' 20% tariffs on Chinese imports relating to fentanyl will remain intact, meaning total tariffs on China will be 30%. U.S. stock markets have faced massive volatility ever since President Donald Trump imposed a 10% baseline tariff on each and every country with which it trades. Tariff rates were much higher for several major trading partners of the United States. The Conference Board reported that the U.S. leading indicator fell by 1% in April compared with the consensus estimate of a decline of 0.9%. The metric for March was revised downward to a drop of 0.8% from a decline of 0.7% reported earlier. The composite index of leading indicators, which is derived from 10 leading indicators, signals the turning points in the economy and forecast economic cycles. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
